NCT00417833

Brief Summary

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Dec 2005

Shorter than P25 for phase_2

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2005

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2006

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 3, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 4, 2007

Completed
Last Updated

June 3, 2024

Status Verified

May 1, 2024

First QC Date

January 3, 2007

Last Update Submit

May 31, 2024

Conditions

Diabetic Proliferative RetinopathyVascular Vein OclussionChoroidal Neovascularization

Interventions

Intravitreal BevacizumabDRUG

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization
  • Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment
  • Completely studies

You may not qualify if:

  • Complications
  • Tractional Detachment
  • Endophthalmitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Choroidal Neovascularization

Condition Hierarchy (Ancestors)

Choroid DiseasesUveal DiseasesEye DiseasesNeovascularization, PathologicMetaplasiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Myrian L Hernández, MD

    Asociación para Evitar la Ceguera en México

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 3, 2007

First Posted

January 4, 2007

Study Start

December 1, 2005

Study Completion

July 1, 2006

Last Updated

June 3, 2024

Record last verified: 2024-05